Molecular Imaging Market

Molecular Imaging Market Forecast and Outlook By FMI

In 2025, the molecular imaging market was valued at USD 5,686.4 million. Based on Future Market Insights' analysis, demand for molecular imaging is estimated to grow to USD 6,112.9 million in 2026 and USD 12,598.9 million by 2036. FMI projects a CAGR of 7.5% during the forecast period.

Absolute dollar growth of USD 6,486.0 million over the decade positions molecular imaging among the faster-growing segments in diagnostic capital equipment and radiopharmaceuticals. The growth trajectory is shaped by two converging forces: the expansion of PET/CT and PET/MR installed bases in oncology and neurology, and the emergence of theranostics, where the same molecular target is used for both imaging and therapy (https://www.futuremarketinsights.com/reports/theranostics-market). Radiopharmaceutical supply chain investments, particularly in Lutetium-177 and Actinium-225 production, are enabling clinical-scale delivery of radioligand therapies.

Summary of Molecular Imaging Market

• Molecular Imaging Market Definition
  • The market covers imaging hardware (PET, SPECT, PET/CT, PET/MRI), radiopharmaceuticals (diagnostic tracers and therapeutic isotopes), and associated software for molecular-level disease visualization used in oncology, cardiology, neurology, and theranostics applications.
• Demand Drivers in the Market
  • Theranostic agent approvals (Lu-177 PSMA, Lu-177 DOTATATE) are converting diagnostic imaging into therapeutic revenue platforms.
  • Total-body PET scanner installations are reducing scan times and enabling new research and clinical throughput levels.
  • Alzheimer diagnostic imaging (amyloid and tau PET) is opening a large neurology indication with aging population demographics.
• Key Segments Analyzed in the FMI Report
  • Modality: PET/CT holds the largest installed base share, PET/MRI is the fastest-growing premium segment.
  • Application: Oncology accounts for the majority of molecular imaging procedures globally.
  • Geography: North America leads by cyclotron density and tracer access, Asia Pacific is fastest-growing by scanner installations.
• Analyst Opinion at FMI
  • Principal Consultant at Future Market Insights opines, 'In the updated Molecular Imaging Market Report for 2026 to 2036, CXOs will find that molecular imaging is transitioning from diagnostic ancillary to therapeutic platform. My findings point at theranostic agent commercialization and total-body PET adoption as the two forces creating new revenue layers on top of existing installed base economics.'
• Strategic Implications/Executive Takeaways
  • Invest in radiopharmaceutical manufacturing capacity to capture theranostic dose supply margins.
  • Evaluate total-body PET scanners for high-throughput imaging centers and pharmaceutical trial sites.
  • Build cyclotron network access for short-half-life tracer distribution to expand geographic coverage.
• Methodology
  • Validated through IAEA cyclotron database and FDA radiopharmaceutical approval records.
  • Zero reliance on speculative third-party market research reports.
  • Based on hospital imaging utilization data, isotope production statistics, and scanner installation benchmarks.

In August 2024, Siemens Healthineers made a binding offer to acquire Novartis's Advanced Accelerator Applications (AAA) molecular imaging business for over EUR 200 million [1]. This acquisition consolidates Siemens' position across the theranostics value chain, from imaging hardware through isotope production to clinical delivery. The deal reflects the broader industry pattern of equipment OEMs moving upstream into radiopharmaceutical manufacturing to capture recurring consumable revenue.

India (9.2% CAGR) and China (8.8% CAGR) lead growth as public hospital networks expand nuclear medicine departments and PET/CT installations. The United States (7.2% CAGR) sustains demand through Medicare coverage expansion for PET-based oncology staging and Alzheimer's amyloid imaging (https://www.futuremarketinsights.com/reports/alzheimers-disease-diagnostic-market). Germany (6.8% CAGR) and France (6.5% CAGR) contribute via theranostics adoption in university medical centres. Japan (6.3% CAGR) grows through cyclotron network expansion and radiopharmaceutical manufacturing investment by GE HealthCare following its Nihon Medi-Physics acquisition.

Molecular Imaging Market Definition

The molecular imaging market covers equipment, radiopharmaceuticals, and software used to visualize biological processes at the molecular and cellular level in living subjects. This includes PET scanners, SPECT cameras, PET/CT and PET/MR hybrid systems, optical imaging platforms, contrast agents, radioactive tracers, and image reconstruction and analysis software. The market spans diagnostic applications in oncology, cardiology, and neurology, as well as pharmaceutical R&D use in drug development and clinical trials.

Molecular Imaging Market Inclusions

Global and regional market sizes by value for 2026 to 2036. Breakdowns by imaging type, application, end user, and region. Installed base tracking, radiopharmaceutical pricing analysis, and cyclotron infrastructure mapping.

Molecular Imaging Market Exclusions

General-purpose CT, MRI, and X-ray systems without molecular imaging functionality are excluded. Non-diagnostic uses of radioactive isotopes (industrial radiography, sterilization) are outside scope. Consumer health wearables and non-clinical wellness imaging are excluded.

Molecular Imaging Market Research Methodology

• Primary Research: Interviews with nuclear medicine physicians, hospital radiology directors, cyclotron operators, and radiopharmaceutical manufacturing executives.
• Desk Research: FDA and EMA radiopharmaceutical approval databases, IAEA nuclear medicine infrastructure reports, and peer-reviewed oncology imaging literature.
• Market-Sizing and Forecasting: Hybrid model combining PET/CT installed base estimates with scan volume and radiopharmaceutical dose pricing, validated against OEM revenue disclosures and hospital CAPEX budgets.
• Data Validation and Update Cycle: Cross-referenced against IAEA NUMDAB (Nuclear Medicine Database), company quarterly earnings, and national health expenditure reports.

Molecular Imaging Market Segment Outlook

By Modality

SPECT Dominates the Market Due to its Advanced Molecular Imaging with Versatility and Cost-Effectiveness

Single Photon Emission Computed Tomography (SPECT) still stands high against molecular imaging because of its cost-effectiveness and versatility. SPECT imaging has extensive applications in cardiology, neurology, and oncology while feeding back information that is helpful in functional and physiological domains.

The growing use of radiopharmaceuticals like Technetium-99m, advances made in SPECT-CT hybrid imaging, and new prospects in quantitative imaging will drive market growth. Moreover, using artificial intelligence for image analysis and enhancement will add to diagnostic accuracy. The other added advantage is the rise of theranostics that supports SPECT in this fast-changing field of molecular imaging.

The Rising Adoption of Hybrid Molecular Imaging due to Enhanced Diagnostic Precision and Clinical Applications

Hybrid imaging systems, such as fusion and other imaging modalities, have become popular. Fusing functional and anatomical information that works to accomplish these sets these systems apart from the normal imaging modalities. In addition to staging and localization of disease, one good use is in oncology, neurology, and cardiovascular imaging by merging metabolic information with high-resolution anatomical information.

The increasing adoption of AI data-driven hybrid imaging platforms, rapid advances in detector technology, and growing opportunities in multimodal imaging in PM are augmenting the future growth of this segment. The wider applications in theranostics and drug research push demand further for hybrid molecular imaging products.

By Application

Oncology Dominating the Market with Rising Cancer Prevalence and Precision Medicine Adoption

The field of oncology has received much impetus from the increased incidence of cancer and rising demand for early diagnosis and an accurate assessment of tumors in a global arena. Allowing for visualization of tumorous growth, detection, staging, treatment planning, and assessment, Siemens Molecular Imaging focuses on PET, SPECT, and hybrid PET-CT/MRI systems.

There is rising application of radiopharmaceuticals in cancer imaging, AI-based imaging analytics, and advances in targeted radiotracers for specific cancers, fostering market growth. Theranostic strategies integrating molecular imaging and targeted radiotherapy are also poised to metamorphose destiny in oncology for imaging.

Neurology is an Emerging Segment as it is Expanding its Role in the Early Diagnosis of Neurodegenerative Diseases.

Neurology is on course to become the next high growth platform for the molecular imaging market; a growing incidence of Alzheimer's, Parkinson's disease, epilepsy, and multiple sclerosis is driving that growth. PET/SPECT modalities are seminal in identifying abnormal protein deposits, brain metabolomic profiling, assessing neurodegenerative diseases, and determining functional deficiencies.

Demand for neuroimaging via molecular imaging will be driven by increasing usage of amyloid and tau PET imaging for Alzheimer's diagnosis, along with ongoing development of new radiotracers for neuroinflammation and incorporation into AI-driven image analysis. Moreover, increased use of molecular imaging for drug discovery and pharmaceutical clinical trials will further sustain growth.

Regional Market Trends

North America

North America is also anticipated to possess a commanding market share for molecular imaging throughout the forecast period. This supremacy can be put down to a robust healthcare structure, healthy investment in R&D, and a high prevalence of chronic diseases that require advanced diagnostic solutions, thereby fueling this market.

The United States is expected to be a key contributor to this market, mainly because of the presence of some major players in the market and a firm accent on technological innovations. Furthermore, this region is spurred on by promoting early detection and prevention of diseases and personalized medicine.

On the other hand, image equipment costs and procedures may handicap access to molecular imaging modalities for populations with little or no medical insurance. Moreover, the stringent regulatory requirements may easily impose barriers to market entry and hinder the approval of new imaging agents.

Europe

Europe is sharing a massive part in the market for molecule imaging, with rising health care spending, an increase in the prevalent segment of aged populaces, and rousing cases of chronic diseases having their roots there. Germany, France, and the United Kingdom lead, with calibrated healthcare systems and involvement in medical research.

The region benefits from the collaboration between academia and industry in new imaging technologies and the development of new radiotracers. However, the huge income gaps in the various European regions will continue to lead to uneven access to advanced imaging modalities. Shameless exploitation of the intricate regulatory structure of the European Union leads to several challenges for the manufacturers.

Asia-Pacific

The Asia-Pacific region is expected to rise quickly during the predicted years for the molecular imaging market. This boom could be attributed to increased investment and development in healthcare infrastructure and increasingly enhanced health awareness and recognition for early detection or diagnosis of disease.

Countries like China, India, and Japan witness a growing prevalence of chronic diseases, which increases the demand for sophisticated diagnostic modalities. The government initiatives toward better healthcare services and research collaborations providing positive results will also support market growth.

However, challenges such as limited access to modern healthcare in rural regions, economic disparities, and immense variability in regulatory frameworks among the nations may restrain the penetration into the market.

Nonetheless, this region presents huge opportunities for growth through value-based partnerships, in-country product development, and educated initiatives to promote the benefits of molecular imaging while overcoming challenges.

Challenges and Opportunities

Challenges

Frequent Product Recalls Hampers the Molecular Imaging

Product recall and safety concerns due to the adverse events associated with molecular imaging, including side effects, may hamper the growth of the global molecular imaging market.

The stringent rules and regulations by the USA Food and Drug Administration, such as (FDA) 510 (K) for molecular imaging devices and the European Commission for new product launches and marketing and sales activities may hinder the growth of the global molecular imaging market. The higher price of molecular imaging devices may also become a cost restraint for the global market over the forecast period.

Opportunities

Increasing Focus on Personalized Medicine Expands the Opportunities in the Molecular Imaging Market

Growing attention on personalized medicine presents opportunities for imaging agent design customized to an individual's disease biomarker, with heightened diagnostic specificity and treatment effectiveness.

Technological advancements, including combinations of artificial intelligence and machine learning, are opening doors to innovative possibilities for the analysis and interpretation of images, workflow efficiency, and diagnostic accuracy. Furthermore, increasing numbers of people developing chronic diseases all over the world make necessary more and better diagnostic methods of early recognition with timely treatment.

Partnerships among pharmaceutical, research institutes, and medical device corporations could develop innovative new imaging probes and help further utilize molecular imaging to target areas such as new treatments and targeted drugs. Furthermore, growth in emerging markets and the creation of affordable imaging solutions specific to these markets hold significant growth opportunities.

Advancing Precision Medicine: The Evolving Landscape of Molecular Imaging:

The market has transformed in many ways, with new hybrid recording devices such as PET/MRI and PET/CT improving diagnostic accuracy in early disease identification. Targeted molecular imaging agents,including radiopharmaceuticals, have enhanced diagnosis in oncology, cardiology, and neurology. It also allows individualized therapeutic regimens based on genetics.

The continued placement of molecular imaging in preclinical investigations and clinical trials has only solidified the position of molecular imaging in drug discovery. Improved image processing algorithms enhance digital data interpretation, thus improving patient outcomes.

Emerging Trends in Molecular Imaging

New trends within molecular imaging have shifted to focusing early on detecting disease-increasingly-or, for many of these cases, cancers and diseases related to the nervous system. Theranostics is the new word for combining a diagnostic procedure and therapy.

AI integration improves the quality of image analysis and, hence, diagnostic performance, while utilizing portable imaging devices expands the accessibility of these technologies for deployable point-of-care use.

Brief Market Overview

The molecular imaging market was predicted to grow between 2020 and 2024 owing to the increased demand for early-stage disease diagnosis due in part to commercialized innovations in imaging agents and a general increase in hybrid system adoption.

For oncology, cardiology, and neurology applications, PET, SPECT, and optical imaging systems gained increasing application as the systems improved disease detection and effective treatment planning. AI-related innovations in image analysis offered further innovative and accurate radiotracers for sophisticated disease diagnostics.

On the downside, equipment costs have proved high, with those most promising potentials equally challenged by regulatory barriers and disruptions in supply chains related to radiopharmaceuticals.

One will witness the market characterized by AI-enabled image processing, improved specificity next-gen tracers, and broader avenues on molecular imaging into personalized medicine during 2025 to 2035. Regulatory agencies will streamline new guidelines around approvals for imaging agents and AI-driven diagnostics.

An increase in investments in theranostics-those combined therapy and diagnostics- will thus contribute to the market's growth. Sustainability efforts would entail a reduction in radioactive wastes and the creation of eco-friendly imaging materials. Localized radiopharmaceutical production and establishing multinational distribution networks would also achieve resilience in the supply chain.

Shifts in the Molecular Imaging Market from 2020 to 2024 and Future Trends (2025 to 2035)

Category	2020 to 2024 Trends
Regulatory Landscape	Strict FDA and EMA approvals for new tracers and imaging systems; growing emphasis on patient safety.
Technological Advancements	Growth of hybrid imaging (PET-CT, PET-MRI), AI-powered image analysis, and development of novel radiotracers.
Consumer Demand	Increased adoption in oncology, cardiology, and neurology for early disease detection.
Market Growth Drivers	Improved imaging technology increases chronic disease prevalence and health care costs.
Sustainability	Limited focus on sustainability; challenges in managing radioactive waste from tracers.
Supply Chain Dynamics	Dependence on centralized radiopharmaceutical production; occasional shortages due to supply chain disruptions.

Category	2025 to 2035 Projections
Regulatory Landscape	Streamlined regulatory processes for AI-driven diagnostics and next-generation radiotracers.
Technological Advancements	Expansion of AI-driven image interpretation, high-resolution molecular imaging, and targeted theranostics.
Consumer Demand	Increasingly applied in personalized medicine, regenerative medicine, and treatment by AI-assisted precision diagnostics.
Market Growth Drivers	Expansion into emerging markets, increased focus on theranostics, and novel PET and SPECT tracers development.
Sustainability	Development of eco-friendly tracers, reduced radiation exposure imaging techniques, and sustainable disposal methods.
Supply Chain Dynamics	Diversified radiotracer production, localized manufacturing, and improved global distribution networks.

Country-wise Insights

United States

Market Outlook

The molecular imaging market is big in the states and astonishing; the growth rate of this development, however, is still very much dependent upon the interesting number of patients suffering from chronic diseases such as cancer and cardiovascular disorders. Better performance in imaging technologies will again make resistant to early disease diagnosis and personalized treatment approaches. However, high costs and varied regulations may hinder market expansion.

Market Growth Factors

• High Incidence of Chronic Diseases: High Prevalence of Chronic Diseases: The karmic competition for advanced diagnostic tools to help in the late detection of disorders, such as cancer cardiovascular diseases or neurological disorders, shifts to the developing world by their respective governments.
• Technical Advances: The contemporary imaging modalities that present continuous innovation, including, among others, AI-driven image reconstruction and hybrid imaging systems, are geared toward changes in diagnostic accuracy and patient outcomes, thereby increasing productivity in health care.
• Government Initiatives: With supportive policies, funding, and approvals for new radiopharmaceuticals, the government is anticipated further to sustain the growth of the molecular imaging market.
• Aging Population: With the increasing geriatric population, the occurrences of chronic diseases related to old age cases have risen, which otherwise has, along these lines, increased the demand for advanced precise and non-invasive imaging diagnostic solutions.
• Healthcare Infrastructure: The existence of a well-established healthcare system, along with investments in advanced medical technology and imaging facilities, is facilitating an appropriate cash flow from support for developing into widespread acceptance by clinical applications for molecular imaging technology.

Market Forecast

Country	CAGR (2025 to 2035)
USA	7.2%

Germany

Market Outlook

Germany's molecular imaging market is expanding due to a robust healthcare infrastructure and a strong focus on medical technology innovation. Although the diagnostic imaging and molecular imaging markets in Germany are growing with robust healthcare infrastructure and supporting medical technology innovation, growth could be inhibited by stringent regulatory frameworks and high costs.

Market Growth Factors

• Advanced Healthcare System: Germany already has a very developed health system with advanced medical facilities and specialized diagnostic centers, which helps mold the introduction of new molecular imaging tools with ease of integration.
• Government Support: Factors boosting the adoption of molecular imaging technologies nationwide are the government's pro-molecular imaging policies, funding programs for early diagnosis and management of diseases, and other initiatives.
• Technological Integration: New design systems developed by hybrid, AI-assisted imaging technologies are improving diagnostics, keeping the advanced techniques in mind and positively changing patient outcomes.
• Patient Awareness: Growing knowledge among patients for the early detection of diseases will cater to an increase in demand for molecular imaging owing to the rising access to modern diagnostic services.
• Aging Population: The growing and steadily increasing elderly population accounts for rising incidences of chronic diseases such as cancer and cardiovascular disease, thereby doing good for advanced imaging.

Market Forecast

Country	CAGR (2025 to 2035)
Germany	7.8%

India

Market Outlook

India's molecular imaging market is primed for immense growth, propelled by a growing number of cases of chronic diseases and growing healthcare awareness. Together with an increase in the number of healthcare facilities and the actions taken by the government to improve disease diagnosis, this opens up further market development possibilities. However, the low availability of advanced treatments in rural areas may slow market growth.

Market Growth Factors

• Increasing Chronic Disease Cases: A growing number of patients with conditions like cancer and cardiovascular diseases leads to higher demand for advanced imaging solutions.
• Government Health Programs: Initiatives to improve disease diagnosis and on-site preventive care support market demand.
• Medical Tourism: India's reputation as a medical tourism hub attracts patients seeking affordable diagnostic procedures.
• Technological Adoption: Increased use of molecular imaging devices improves treatment outcomes.

Market Forecast

Country	CAGR (2025 to 2035)
India	8.6%

China

Market Outlook

The incredibly vast molecular imaging market growth in China rests on the larger patient base suffering from chronic diseases and increasing healthcare investment. Focus on improving healthcare access and the rigorous adoption of advanced medical technologies also contribute to the market growth rate.

Nevertheless, there is a disparity across different regions about healthcare delivery quality, especially between urban areas and Congress and rural areas, which might pose huge challenges.

Market Growth Factors

• Large Patient Population: A significant number of individuals with chronic diseases drive demand for advanced imaging technologies.
• Economic Development: Rising incomes and improved healthcare infrastructure enhance access to advanced treatments.
• Government Initiatives: Policies to expand healthcare coverage and improve disease management support market growth.
• Technological Advancements: Local manufacturers are developing cost-effective molecular imaging solutions.
• Medical Tourism: China's emergence as a destination for medical procedures boosts demand for advanced imaging technologies.

Market Forecast

Country	CAGR (2025 to 2035)
China	8.9%

Brazil

Market Outlook

Brazil's molecular imaging market is growing on the back of an improved system of healthcare infrastructures and an accompanying increased incidence of chronic diseases.

The shift towards advanced imaging technologies by the majority and the government initiatives to increase healthcare access contribute to the expansion of the market. Economic disparities and regional differences in health may pose obstacles to some extent.

Market Growth Factors

• High Chronic Disease Burden: A significant number of patients with conditions like cancer and cardiovascular diseases lead to increased demand for advanced imaging technologies.
• Healthcare Infrastructure Investments: Development of medical facilities increases access to advanced diagnostic treatments.
• Government Health Initiatives: Policies promoting early disease detection and management support market growth.
• Private Healthcare Expansion: Growth in private hospitals and clinics enhances the availability of advanced imaging devices.
• Technological Advancements: Adoption of innovative imaging technologies improves patient outcomes.

Market Forecast

Country	CAGR (2025 to 2035)
Brazil	6.5%

Competitive Outlook

The expanding role of molecular imaging in oncology, cardiology, and neurology, the technical development of imaging technology, and the increasing need for early disease diagnosis are contributing factors to the growth of the molecular imaging market. Meanwhile, leading companies in the market are investing in improvements, regulatory approvals, and strategic alliances to secure their market exclusivity.

The market is highly competitive, and medical imaging companies are heavily investing in the next generations' of molecular imaging technologies.

Recent Developments:

• In February 2026, global imaging investment exceeded 51,900 funding rounds, with NVIDIA deploying USD 4.4 billion across 25 companies for autonomous diagnostic imaging [2].
• In January 2025, Lantheus signed a definitive agreement to acquire Life Molecular Imaging for USD 350 million to expand its Alzheimer's radiodiagnostic portfolio [3].
• In December 2024, GE HealthCare acquired Nihon Medi-Physics from Sumitomo Chemical to strengthen radiopharmaceutical development capabilities [4].
• In October 2024, Siemens Healthineers collaborated with CHU de Nantes for personalized cancer care innovations in diagnostic and interventional imaging [5].
• In September 2024, the FDA approved Flyrcado (flurpiridaz F 18), a PET myocardial perfusion imaging agent for coronary artery disease detection [6].

Market Share Analysis by Company

Company Name	Estimated Market Share (%)
GE Healthcare	17.0%
Siemens Healthineers	9.5%
Philips Healthcare	10.0%
Bruker Corporation	2.3%
Other Companies (combined)	61.2%

Key Company Developments and Activities

Company Name	GE Healthcare
Year	2025
Key Developments/Activities	The company emphasizes new product launches and up-gradation of existing products and software to expand its product offerings to the end users and revenue generation

Company Name	Siemens Healthineers
Year	2024
Key Developments/Activities	The company focuses on consolidation activities and expansion activities to expand its geographical presence across the world to en-cash the growing opportunities in the healthcare IT industry

Company Name	Philips Healthcare
Year	2024
Key Developments/Activities	The company focuses on partnerships and collaboration activities to increase the product reach to the end users and to increase the growth in revenue

Company Name	Bruker Corporation
Year	2025
Key Developments/Activities	The company emphasizes new product development and up-gradation of the existing devices and software to cater to the increasing demand for molecular imaging and diagnostics industry

Key Company Insights

GE Healthcare (17.0%)

GE Healthcare leads the molecular imaging market with a strong portfolio of PET, SPECT, and hybrid imaging solutions that integrate AI for enhanced diagnostic accuracy.

Siemens Healthineers (9.5%)

Siemens Healthineers specializes in high-performance molecular imaging technologies, focusing on oncology, neurology, and cardiology applications.

Philips Healthcare (10.0%)

Philips provides advanced hybrid imaging systems with accurate diagnostics, allowing for improved clinical decision-making through AI-driven analytics.

Bruker Corporation (2.3%)

Bruker is recognized for producing high-resolution preclinical imaging systems for drug development and research organizations and pharmaceutical companies.

Other Key Players (61.2% Combined)

Beyond the leading companies, several other manufacturers contribute significantly to the market, enhancing product diversity and technological advancements. These include:

• Fujifilm Holdings Corporation
• Toshiba Medical System Corp.
• Hitachi Medical Corp.
• Position Corporation
• Esaote SpA
• Other

Scope of the Report

Metric	Value
Quantitative Units	USD 6,112.9 million (2026) to USD 12,598.9 million (2036), at a CAGR of 7.5%
Key Companies	Siemens Healthineers, GE HealthCare, Philips, Lantheus Holdings, Cardinal Health, Bracco Imaging, Bruker Corporation, United Imaging Healthcare, Eczacibasi-Monrol, Bayer Radiopharmaceuticals
Forecast Period	2026 to 2036

Key Segments

By Modality Type:

• PET
• PET-CT
• PET-MR
• SPECT
• Software
• Magnetic resonance spectroscopy
• Molecular ultrasound imaging

By Application:

• Cardiology
• Oncology
• Gastrointestinal disorders
• Neurological disorders
• Others

By End User:

• Hospitals
• Ambulatory surgical centers
• Diagnostics imaging centers

By Region:

• North America
• Latin America
• East Asia
• South Asia & Pacific
• Western Europe
• Eastern Europe
• Middle East & Africa

Bibliography

• [1] Siemens Healthineers. AAA Acquisition Offer. August 2024.
• [2] NVIDIA. AI Imaging Investment Portfolio. February 2026.
• [3] Lantheus Holdings. Life Molecular Imaging Acquisition. January 2025.
• [4] GE HealthCare. Nihon Medi-Physics Acquisition. December 2024.
• [5] Siemens Healthineers. CHU de Nantes Collaboration. October 2024.
• [6] USA FDA. Flyrcado (flurpiridaz F 18) Approval. September 2024.
• [7] IAEA. Nuclear Medicine Database (NUMDAB). 2025.
• [8] WHO. Global Cancer Observatory. 2025.
• [9] Future Market Insights. Theranostics Market Report.
• [10] Future Market Insights. Nuclear Medicine Equipment Market.
• [11] Future Market Insights. Alzheimers Disease Diagnostic Market.
• [12] European Association of Nuclear Medicine. Annual Congress Proceedings. 2025.

This Report Addresses

• Market intelligence across PET, SPECT, and optical molecular imaging segments
• 10-year forecasts from 2026 to 2036 validated against IAEA infrastructure data
• Growth mapping across oncology, cardiology, and neurology applications
• Competition assessment including theranostics integration, cyclotron ownership, and OEM service models
• Radiopharmaceutical supply chain analysis: Mo-99 reactor capacity, Lu-177 production, cyclotron density
• Regulatory tracking: FDA novel tracer approvals, EMA radioligand therapy guidelines
• Regional installed base and reimbursement landscape analysis
• Report delivery in PDF, Excel, PPT, and interactive dashboard formats